We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
-14.6%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$68.5B
AUM Growth
-$9.16B
Cap. Flow
+$4.06B
Cap. Flow %
5.93%
Top 10 Hldgs %
21.45%
Holding
3,375
New
359
Increased
2,433
Reduced
285
Closed
282

Top Buys

Rank Stock Value
1
LIN icon
Linde
LIN
+$124M
2
AAPL icon
Apple
AAPL
+$110M
3
MSFT icon
Microsoft
MSFT
+$104M
4
AMZN icon
Amazon
AMZN
+$71.3M
5
WBD icon
Warner Bros
WBD
+$69.6M

Top Sells

Rank Stock Value
1
T icon
AT&T
T
+$61.6M
2
CERN
Cerner Corp
CERN
+$50.9M
3
NXPI icon
NXP Semiconductors
NXPI
+$31.4M
4
AZPN
ASPEN TECHNOLOGY INC
AZPN
+$30.4M
5
YUMC icon
Yum China
YUMC
+$16.3M

Sector Composition

Rank Sector Weight
1 Technology 23.13%
2 Healthcare 14.42%
3 Financials 13.45%
4 Consumer Discretionary 10.49%
5 Industrials 9.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ARAY icon
3076
Accuray
ARAY
$33.8M
$22K ﹤0.01%
11,438
-87,572
-88% -$219K
TALK icon
3077
Talkspace
TALK
$873M
$20K ﹤0.01%
+11,602
New +$17.4K
WEJO
3078
DELISTED
Wejo Group Limited Common Shares
WEJO
$20K ﹤0.01%
+16,525
New +$38.6K
BLRX
3079
BioLineRX
BLRX
$12.1M
$19K ﹤0.01%
364
APLD icon
3080
Applied Digital
APLD
$8.31B
$15K ﹤0.01%
+14,352
New +$43K
ZOM
3081
DELISTED
Zomedica Corp.
ZOM
$15K ﹤0.01%
+69,911
New +$17.8K
MMAT
3082
DELISTED
Meta Materials Inc. Common Stock
MMAT
$14K ﹤0.01%
136
-1,915
-93% -$286K
EMBK
3083
DELISTED
Embark Technology, Inc. Common Stock
EMBK
$8K ﹤0.01%
+766
New +$44.7K
ABOS icon
3084
Acumen Pharmaceuticals
ABOS
$165M
-20,273
Closed -$79K
ACIC icon
3085
American Coastal Insurance
ACIC
$486M
-26,809
Closed -$89K
ACTG icon
3086
Acacia Research
ACTG
$456M
-79,590
Closed -$359K
ADN
3087
DELISTED
Advent Technologies
ADN
-503
Closed -$35K
ADVM
3088
DELISTED
Adverum Biotechnologies
ADVM
-11,921
Closed -$156K
AGS
3089
DELISTED
PlayAGS
AGS
-36,004
Closed -$240K
AKBA icon
3090
Akebia Therapeutics
AKBA
$264M
-205,062
Closed -$147K
ALDX icon
3091
Aldeyra Therapeutics
ALDX
$95.9M
-47,596
Closed -$212K
ALGS icon
3092
Aligos Therapeutics
ALGS
$34.1M
-681
Closed -$37K
ALLK
3093
DELISTED
Allakos
ALLK
-36,104
Closed -$206K
ALT icon
3094
Altimmune
ALT
$585M
-50,234
Closed -$306K
AMSC icon
3095
American Superconductor
AMSC
$1.59B
-35,760
Closed -$272K
ANNX icon
3096
Annexon
ANNX
$918M
-38,917
Closed -$106K
AOUT icon
3097
American Outdoor Brands
AOUT
$157M
-21,184
Closed -$278K
APLT
3098
DELISTED
Applied Therapeutics
APLT
-17,409
Closed -$37K
APYX icon
3099
Apyx Medical
APYX
$175M
-27,228
Closed -$178K
AQB icon
3100
AquaBounty Technologies
AQB
$5.51M
-2,807
Closed -$105K

Similar funds

RhumbLine Advisers's Q2 2022 Portfolio in Review

As of Q2 2022, RhumbLine Advisers held 3,375 positions worth $68.5B, down 12% from $77.7B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

RhumbLine Advisers deployed $4.06B of net new capital in Q2 2022, opening 359 new positions and adding to 2,433 existing holdings. Its largest new stake was Aspen Technology Inc: 81,883 shares worth $15M.

By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was AT&T, an estimated $61.6M trimmed.

  • RhumbLine Advisers's largest Q2 2022 buy was Aspen Technology Inc: 81,883 shares worth $15M.
  • RhumbLine Advisers added most to Linde in Q2 2022, an estimated $124M increase.
  • RhumbLine Advisers's biggest Q2 2022 reduction was AT&T, cutting an estimated $61.6M.
  • RhumbLine Advisers fully exited Cerner Corp in Q2 2022, selling an estimated $50.9M.
  • RhumbLine Advisers's ten largest holdings make up 21% of its $68.5B portfolio in Q2 2022.
  • RhumbLine Advisers opened 359 new positions and closed 282 in Q2 2022.
  • RhumbLine Advisers's portfolio value fell 12% quarter-over-quarter to $68.5B.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.